For how we live.
Pooling 58 randomised trials, about 3.5g a day of oat beta-glucan lowered LDL cholesterol by 0.19 mmol/L. A separate meta-analysis of 28 trials found 0.25 mmol/L. Small per person, but consistent.
No long-term trial has tested an all-meat diet. The best direct data is a self-reported survey where people felt better but ran markedly high LDL cholesterol — the signal that should give pause.
Two meta-analyses of dozens of randomised trials agree that about 3 grams a day of oat beta-glucan lowers LDL cholesterol by a small, real amount. The effect is genuine, modest, and dose-dependent.
A 2024 trial randomised heart-risk patients to a dozen eggs a week or almost none. Over four months, blood cholesterol barely moved — echoing an earlier year-long trial in people with diabetes.
Obicetrapib cut Lp(a) by 37% in high-risk patients, a pooled analysis finds, alongside a similar drop in LDL. It reaches a lipid the costly new injectables target, if far less deeply.
In 408,039 UK Biobank participants, carrying loss-of-function variants in both LPA and PCSK9 was tied to markedly lower coronary disease risk than either alone — a genetic case for combination therapy.
In the Novartis-funded VICTORION-Challenge trial, twice-yearly inclisiran cut LDL 56.3% at day 150 against 15.4% for daily bempedoic acid — an open-label comparison of a surrogate marker, not outcomes.
In the phase 3 CORALreef AddOn head-to-head, enlicitide dropped LDL cholesterol 64.6% at day 56 — far past ezetimibe, bempedoic acid, or the two combined.
VESALIUS-CV randomised 12,257 patients with atherosclerosis or diabetes but no prior MI or stroke. Evolocumab reduced the three-point event rate from 8.0% to 6.2% over a median 4.6 years.